Abstract：
BACKGROUND: Bacterial vaginosis (BV) is difficult to eradicate due to BV biofilms protecting BV bacteria (Gardnerella, Prevotella, and other genera). With the growing understanding of biofilms, we systematically reviewed the current knowledge on the efficacy of anti-BV biofilm agents.
METHODS: We searched literature in the Scopus, Medline, and Embase databases for empirical studies investigating substances for the treatment of BV biofilms or prevention of their recurrence and their efficacy and/or safety.
RESULTS: Of 201 unique titles, 35 satisfied the inclusion criteria. Most studies (89%) reported on preclinical laboratory research on the efficacy of experimental antibiofilm agents (80%) rather than their safety. Over 50% were published within the past 5 years. Agents were classified into 7 groups: antibiotics, antiseptics, cationic peptides, enzymes, plant extracts, probiotics, and surfactants/surfactant components. Enzymes and probiotics were most commonly investigated. Earlier reports of antibiotics having anti-BV biofilm activity have not been confirmed. Some compounds from other classes demonstrated promising anti-BV biofilm efficacy in early studies.
CONCLUSIONS: Further research is anticipated on successful antibiofilm agents. If confirmed as effective and safe in human clinical trials, they may offer a breakthrough in BV treatment. With rising antibiotic resistance, antibiofilm agents will significantly improve the current standard of care for BV management.
METHODS: We searched literature in the Scopus, Medline, and Embase databases for empirical studies investigating substances for the treatment of BV biofilms or prevention of their recurrence and their efficacy and/or safety.
RESULTS: Of 201 unique titles, 35 satisfied the inclusion criteria. Most studies (89%) reported on preclinical laboratory research on the efficacy of experimental antibiofilm agents (80%) rather than their safety. Over 50% were published within the past 5 years. Agents were classified into 7 groups: antibiotics, antiseptics, cationic peptides, enzymes, plant extracts, probiotics, and surfactants/surfactant components. Enzymes and probiotics were most commonly investigated. Earlier reports of antibiotics having anti-BV biofilm activity have not been confirmed. Some compounds from other classes demonstrated promising anti-BV biofilm efficacy in early studies.
CONCLUSIONS: Further research is anticipated on successful antibiofilm agents. If confirmed as effective and safe in human clinical trials, they may offer a breakthrough in BV treatment. With rising antibiotic resistance, antibiofilm agents will significantly improve the current standard of care for BV management.
摘要：
背景：由于BV生物膜保护BV细菌（Gardnerella，普雷沃氏菌,和其他属)。随着人们对生物膜的了解越来越多,我们系统回顾了目前关于抗BV生物膜药物疗效的知识。
方法：我们在Scopus搜索了文献，Medline,和Embase数据库，用于研究用于治疗BV生物膜或预防其复发的物质及其功效和/或安全性的经验研究。
结果：在201个独特的标题中，35符合纳入标准。大多数研究（89％）报道了临床前实验室关于实验性抗生物膜药物（80％）的功效而不是其安全性的研究。超过50%是在过去5年内发表的。药物分为7组：抗生素，防腐剂,阳离子肽，酶，植物提取物,益生菌，和表面活性剂/表面活性剂组分。酶和益生菌是最常见的研究。具有抗BV生物膜活性的抗生素的早期报道尚未得到证实。来自其他类别的一些化合物在早期研究中表现出有希望的抗BV生物膜功效。
结论：预计将对成功的抗生物膜剂进行进一步研究。如果在人体临床试验中被证实是有效和安全的，他们可能在BV治疗方面取得突破。随着抗生素耐药性的上升，抗生物膜药物将显著改善目前BV管理的护理标准。
方法：我们在Scopus搜索了文献，Medline,和Embase数据库，用于研究用于治疗BV生物膜或预防其复发的物质及其功效和/或安全性的经验研究。
结果：在201个独特的标题中，35符合纳入标准。大多数研究（89％）报道了临床前实验室关于实验性抗生物膜药物（80％）的功效而不是其安全性的研究。超过50%是在过去5年内发表的。药物分为7组：抗生素，防腐剂,阳离子肽，酶，植物提取物,益生菌，和表面活性剂/表面活性剂组分。酶和益生菌是最常见的研究。具有抗BV生物膜活性的抗生素的早期报道尚未得到证实。来自其他类别的一些化合物在早期研究中表现出有希望的抗BV生物膜功效。
结论：预计将对成功的抗生物膜剂进行进一步研究。如果在人体临床试验中被证实是有效和安全的，他们可能在BV治疗方面取得突破。随着抗生素耐药性的上升，抗生物膜药物将显著改善目前BV管理的护理标准。
